Sign In
Buy AXNX
$70.98
+0 (+0%)
At Close: Feb 13, 2025
Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal.
08:18am, Monday, 08'th Jan 2024
The move will expand Boston's product portfolio in its urology business.
Boston Scientific to buy Axonics for $3.7 billion
07:09am, Monday, 08'th Jan 2024
Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.
Axonics to Present at the J.P. Morgan Healthcare Conference
04:01pm, Wednesday, 27'th Dec 2023
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Buy These 4 Low-Beta Stocks to Counter Market Volatility
09:46am, Friday, 15'th Dec 2023
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
Goldman Sachs money manager digs into three themes for long-term growth
11:27am, Tuesday, 05'th Dec 2023
Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, whi
3 Stocks Backed by High Efficiency to Increase Portfolio Returns
08:16am, Wednesday, 29'th Nov 2023
Invest in stocks of Axonics (AXNX), Bel Fuse (BELFB) and Thermon (THR) to tap their high-efficiency levels.
Axonics to Participate in November Investor Conferences
06:00am, Wednesday, 01'st Nov 2023
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics, Inc. (AXNX) Q3 2023 Earnings Call Transcript
10:15pm, Monday, 30'th Oct 2023
Axonics, Inc. (NASDAQ:AXNX ) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Off
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
06:48pm, Monday, 30'th Oct 2023
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.34 per share
5 Top Stocks Set to Beat Q3 Earnings Estimates on Monday
08:16am, Friday, 27'th Oct 2023
We have narrowed our search to five stocks that are set to declare third-quarter earnings on Monday. These are: XPO, ON, WELL, ACGL, AXNX.
Axonics to Report Third Quarter 2023 Financial Results on October 30
06:00am, Monday, 02'nd Oct 2023
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Why Shares of Axonics Rose Friday
12:46pm, Friday, 28'th Jul 2023
Axonics is a medical device company that focuses on bladder and bowel dysfunction therapies. The company also upgraded its annual revenue guidance.
Axonics, Inc. (AXNX) Q2 2023 Earnings Call Transcript
11:27pm, Thursday, 27'th Jul 2023
Axonics, Inc. (NASDAQ:AXNX ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Office
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
06:28pm, Thursday, 27'th Jul 2023
Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.47 per share a year ago.
Axonics to Report Second Quarter 2023 Financial Results on July 27
06:00am, Thursday, 29'th Jun 2023
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
